Cognitive Training Intervention and Attitudes Towards Genetics
NCT ID: NCT03094026
Last Updated: 2025-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2017-08-21
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Internet-Delivered Cognitive Training For Breast Cancer Survivors With Cognitive Complaints
NCT01866813
Feasibility Neurocognitive Outcome After Transplant
NCT02300961
Rehabilitation of Cognitive Changes in Breast Cancer Survivors
NCT01182506
Cognitive Intervention at the End of Therapy for Survivors of Childhood ALL Treated on TOTXVI
NCT03187977
Neurostimulation In Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)
NCT04007601
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Ideally, targeting the intervention and offering it specifically to those at highest risk (integrating clinical and genetic markers) would ensure efficacy. However, evidence is lacking on whether patients are receptive to communication of individual genetic information and whether provision of such results would lead to enhanced intervention response. To realize the high expectations of personalized medicine, patients' preferences and attitudes need to be thoroughly investigated especially as more information on genetic risk becomes available. The investigators will examine patients' genetic knowledge to determine whether factual knowledge of genetics is essential for understanding genetic risk and for informing treatment decision making in this patient population.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
The arm will begin the Lumosity program at enrollment in the study.
Lumosity
Computer-based online cognitive training program using the Lumosity cognitive training program.
Wait List Control
The arm will begin the Lumosity program 3 months after enrollment in the study.
Lumosity (waitlist control)
Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lumosity
Computer-based online cognitive training program using the Lumosity cognitive training program.
Lumosity (waitlist control)
Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Outpatient and between 3 and 6 months post HCT
* English speaking
* Possess access to an internet-connected home computer
Exclusion Criteria
* Participated in neuropsychological intervention within the past 6 months
* History of color blindness
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alabama at Birmingham
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Noha Mohamed Sharafeldin
Prinicipal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Noha M Sharafeldin
Role: PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
X161221006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.